Patents Assigned to Serbig Pharmaceutics Corp.
  • Patent number: 10292956
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 21, 2019
    Assignee: Serbig Pharmaceutics Corp.
    Inventor: Pedro Anastacio Serrano-Ojeda